Navigation Links
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Date:3/25/2008

DEERFIELD, Ill. and VANCOUVER, British Columbia, March 25 /PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. and its co-development partner Cardiome Pharma Corp. (Nasdaq: CRME; TSX: COM) announced the first pivotal Phase III study evaluating the investigational agent KYNAPID(TM) (vernakalant hydrochloride) Injection was published today in Circulation, the official journal of the American Heart Association.

In the study, known as the Atrial arrhythmia Conversion Trial (ACT I), the primary efficacy analysis showed that 75 of the 145 (51.7%) KYNAPID patients in the short-duration atrial fibrillation (AF) group (3 hours to 7 days) converted to sinus rhythm within 90 minutes compared with 3 of the 75 (4.0%) placebo patients. Patients with AF lasting 3 to 48 hours who received KYNAPID demonstrated the highest conversion rate (62.1%) compared with 4.9% with placebo. The median time to conversion to sinus rhythm for the 75 patients receiving KYNAPID who converted was 11 minutes. Only 1 of the 75 KYNAPID-treated patients who converted to sinus rhythm relapsed to AF at 24 hours.

"Due to the importance of treating AF quickly, we're pleased that KYNAPID displayed such a rapid conversion of AF to sinus rhythm," said Edward Pritchett, MD, Consulting Professor of Medicine, Divisions of Cardiology and Clinical Pharmacology, Duke University Medical Center and consultant for Astellas Pharma US.

About ACT I

The Phase III study, referred to as ACT I, was a prospective, randomized, double-blind, placebo-controlled trial of hemodynamically stable patients with symptomatic AF or nontypical atrial flutter, conducted at 44 sites in Canada, the United States and Scandinavia. The study assessed the safety and efficacy of KYNAPID for the
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
9. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
11. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , ... SNY ; EURONEXT: SAN) and the life sciences team ... improve care and outcomes for people with type 1 ... diabetes treatments and devices with Google,s expertise in analytics, ... will explore how to improve diabetes care by developing ...
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... (NYSE: CFN ), a leading, global medical ... to sell its OnSite Services instrument management and ... were not disclosed. (Logo:   http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ... with our strategy to optimize our portfolio of businesses as ...
... 11, 2011 Reportlinker.com announces that a new ... Advanced Drug Delivery Markets (Liposomes, ... http://www.reportlinker.com/p0358466/Advanced-Drug-Delivery-Markets-Liposomes-Polymers-and-Monoclonal-Antibodies.html Drug delivery is evolving ... formulations being discovered frequently. Advanced drug delivery deals ...
Cached Medicine Technology:CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 2CareFusion Announces Sale of OnSite Services Instrument Management and Repair Business 3Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3
(Date:9/1/2015)... OH (PRWEB) , ... September 01, 2015 , ... Mercy ... – has devoted the 10th of its monthly Mercy Health: Helping You Be Well ... affecting one in seven men. , In a concise video on Mercy Health’s ...
(Date:9/1/2015)... ... September 01, 2015 , ... Ogawa’s new massage chairs tout ... more effective and humanlike than ever before. With the goal of bringing wellness to ... the Ogawa Active SuperTrac. , As in its name, the Ogawa Refresh ...
(Date:9/1/2015)... Miramar Beach, FL (PRWEB) , ... September 01, ... ... free pharmacy discount cards, launched its consumer-friendly, informational video this week to coincide ... country: http://www.USAMedicalCard.com/video . , According to the CDC, elementary school children ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic ... products, the VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements ... and Clear. , Formulated with alpha hydroxy acids and natural active ingredients, ...
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully placed one of the ... the last month the FDA has approved two intra-gastric balloons, the ORBERA ™ ... the first incisionless, reversible, weight loss procedures available to Americans. , Dr. ...
Breaking Medicine News(10 mins):Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2
... The scoring system government agencies use to rate ... because they do not take into account the degree ... facilities include a specialized dementia unit according to a ... from Indiana University School of Medicine and the Regenstrief ...
... the University of Michigan Medical School and MedImmune, the ... agreement to work together on a broad range of ... from one of the nation,s top medical research institutions ... developers of biologic therapies. UMMS and MedImmune ...
... viewpoint of the severity of irritable bowel syndrome (IBS) ... of IBS but broader psychological problems, according to a ... the official journal of the American Gastroenterological Association. ... cost-effective manner within tight time constraints and at a ...
... Swedish medical university Karolinska Institutet have developed a new ... kinds of RNA and DNA molecules is a fundamental ... transfer the genetic information in cells. Thus, improved measurement ... cells. It is very difficult to detect small ...
... News) -- Holiday foods and feasts can cause trouble ... disease (GERD), but there are things they can do ... occurs when a faulty valve between the stomach and ... esophagus. Symptoms of GERD include heartburn, acid regurgitation, wheezing, ...
... Nov. 21 (HealthDay News) -- A hand hygiene and cough ... and the number of absences, a new study says. ... program and five schools that received no special hygiene training. ... Flu" program were: , Wash or sanitize your hands ...
Cached Medicine News:Health News:Nursing home quality scorecards don't tell the whole score 2Health News:U-M Medical School and MedImmune join forces to accelerate search for new therapies 2Health News:Psychological factors affect IBS patients' interpretation of symptom severity 2Health News:A better way to count molecules discovered 2Health News:Holiday Foods May Trigger GERD Symptoms 2Health News:School Hygiene Program Reduced Flu Cases 2
High speed, programmable refrigerated centrifuge. High efficiency separations, "Like clockwork" accuracy, aerosol containment, Accommodating, Re-Run control, Glove-Friendly membrane, centrifuge statu...
... 460 family of centrifuges ... that meets a wide ... feature high capacity, versatility ... technology and high safety ...
The Quantum performs centrifugal blood cell separations, urine separations, and sperm cell washing. 24 place angle head, variable speed, and automatic braking system, calibrated variable speed....
... centrifuge is designed especially for ... cover with safety interlock switch, ... emissions, "hold" position for continuous ... motor, maximum stability and compact, ...
Medicine Products: